About Us

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. With a virtual organization and a cost-effective outsourcing model where parts of the operational activities are contracted out to qualified partners, Vivesto has the capacity and competence to develop drugs from early research to the clinic.

Vivesto’s project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

Vivesto is headquartered in Solna, Sweden, and its shares are listed on Nasdaq Stockholm under the Small Cap segment with the ticker VIVE.